1068 VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN SCHISTOSOMIASIS-ASSOCIATED BLADDER CANCER, CORRELATION WITH HISTOPATHOLOGICAL FEATURES AND SCHISTOSOMIASIS

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research III1 Apr 20121068 VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN SCHISTOSOMIASIS-ASSOCIATED BLADDER CANCER, CORRELATION WITH HISTOPATHOLOGICAL FEATURES AND SCHISTOSOMIASIS Hosni Khairy Salem, Hala Ragab, and Nabila Abd El Maksoud Hosni Khairy SalemHosni Khairy Salem Cairo, Egypt More articles by this author , Hala RagabHala Ragab Cairo, Egypt More articles by this author , and Nabila Abd El MaksoudNabila Abd El Maksoud Cairo, Egypt More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1174AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Vascular Endothelial growth factor (VEGF) is a principle growth factor mediating angiogenesis. The high expression of VEGF within bladder tumor is associated with poor prognosis. We determined tissue, plasma and urinary levels of VEGF in patients with bladder cancer to study their correlation with classical clinicopathological factors and to assess its potential role in the evaluation of bladder cancer patients METHODS VEGF was measured by enzyme-linked immunosorbent assay in the tissue, plasma and urine of 100 bladder cancer patients and in corresponding 40 healthy volunteers. Tumor tissue samples were standardized to the protein content and urine samples were normalized for creatinine content. RESULTS Tissue, plasma and urinary VEGF levels were significantly elevated in bladder cancer patients compared to healthy controls (p<0.001). The highest VEGF levels were noted in patients with invasive and poorly differentiated bladder cancer compared to those with superficial and well or moderately differentiated individuals followed by healthy controls. Similarly, we detected the same observation in patients with lymph node metastases signifying that VEGF increases with tumor progression. Also, VEGF levels for schistosomal bladder cancer patients were elevated compared to non-scistosomasl ones (although they were insignificantly different) and healthy controls as they correlated significantly together suggesting that schistosomiasis maybe participates in angiogenic switch. VEGF levels were superior to urine cytology and combined sensitivity between them was the highest (100%) when urine cytology combined with plasma or urinary VEGF. Tissue, plasma and urinary VEGF were significantly correlated together implying that the tumor is the source of plasma and urinary VEGF. CONCLUSIONS Our study demonstrates that strongly expressed VEGF may be relevant for diagnosis of bladder cancer patients, and it is implicated in the pathogenesis of bladder cancer progression. Quantification of urinary VEGF may provide a novel noninvasive marker for the early detection of bladder cancer as well as therapy target. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e433-e434 Peer Review Report Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hosni Khairy Salem Cairo, Egypt More articles by this author Hala Ragab Cairo, Egypt More articles by this author Nabila Abd El Maksoud Cairo, Egypt More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...